PUBLICATIONS

Books, Chapters and Journal Supplements

7. Z Younossi (Guest Editor). Optimization of Adherence to Therapy in Chronic Hepatitis C: Challenges and Emerging Strategies. Cleveland Clinic Journal of Medicine (Supplement), 3 (Vol. 71); 2004.


130. H Gujral, ZM Younossi. Patients with Chronic Hepatitis C and No Health Insurance Coverage. Cleveland Clinic Foundation CME Page, 2007
134. ZM Younossi. Specifically Targeted Antiviral Therapy (STAT-C) for Patients with Chronic Hepatitis C. Medscape Gastroenterology. P1-5. June 1, 2007.
141. Petricoin, ZM Younossi. Reply to the letter to the Editor: Bioinformatics As Tool To Identify Gene/Protein-Pathways Associated With Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis. Hepatology 46(4):1306-1307, 2007


144. CH Kim, ZM. Younossi. Short Duration of Treatment for HCV Genotype 2 or 3 May Diminish Sustained Virologic Response. Evidence Based Gastroenterology 2007, Volume 8, Issue 4:75-77


148. G Aragon, Z Younossi, Telbivudine: Another Option for Treatment of Patients with Chronic Hepatitis B. Evidence Based Gastroenterology 2008; Volume 9, Issue 2:19-22


150. KH Schulz, S Kroencke, H Ewers, H Schulz, ZM Younossi. The Factorial Structure of the Chronic Liver Disease Questionnaire (CLDQ). Qual Life Res. 2008 Apr 4; [Epub ahead of print]


155. CH Kim, ZM Younossi. Non-Alcoholic Fatty Liver Disease. Cleveland Clinic J of Medicine 2008; 75 (9):673-680


158. P Mishra, C Nugent, A Afendy, C Bai, P Bhatia, M Afendy, Y Fang, H Elariny, Z Goodman, ZM. Younossi. Apneic-Hypopneic Episodes during Obstructive Sleep Apnea are Associated with


162. N Rafiq, Z Younossi. Evaluation and Management of Non-alcoholic Fatty Liver Disease. Clinics In Liver Disease 2008 (Accepted)

163. N Rafiq, Z Younossi. Weight Loss and Its Impact on Non-alcoholic Fatty Liver Disease. Seminars in Liver Disease 2008 (Accepted)


165. I Bornman, ZM Younossi. Can the dose of ribavirin be reduced for patients infected with hepatitis C, genotypes 2 and 3? Evidence-Based Gastroenterology 2008

Abstracts and Presentations


70. Z Younossi, S Sarbah, A Di Bisceglie, T Gramlich, P Osmack, A Younoszai, L Grosso, J Cooper, D Duncan, R Seneca. Determination of HFE Mutations in the Paraffin-Embedded Liver Biopsy


121. M Emblom-Callahan, SD Nathan, GM Grant, J Estep, S Ahmad, M Sulkowski, A Afendy, NB Burton, V Chandhoke, Z Younossi. Gene Expression Analysis of Myofibroblasts in End Stage


125. L Ramsey Nader, Chunhong Bai, , Harpreet Gujral, Kathy Terra, Sally McKay, Rochelle Collantes, Janus P. Ong, Robert Sjogren, Zobair M. Younossi Darbepoetin Alfa (DA) and Filgrastim (FL) for the Management of Anemia and Neutropenia of Antiviral Therapy for Chronic Hepatitis C. IDSA Meeting, Toronto, Canada 2006


129. S Bondini, T Gramlich, L Ramsey, JP Ong, D Jondle, N Boparai, H Gujral, ZM Younossi. The Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B. The Impact of

130. Z Younossi. Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B. Association for Study of Liver Disease, Boston, MA. 2006.


160. NL Gerber, J Kallman, CH Kim, R Gupta, ZM Younossi. Demographic, Diagnostic and Disease Characteristics in Patients with Chronic Liver Disease that Correlate with Level of Physical


163. J Michael Estep, Kathy Ankrah, Hazem Elariny, Yun Fang, Vikas Chandhoke, Ancha Baranova, Zobair M. Younossi. Inflammatory Cytokine Gene Expression in the Visceral Adipose Tissue of NASH Patients with Type II Diabetes and/or Fibrosis. Mid-Atlantic Diabetes Symposium, National Institutes of Health, Bethesda, MD 2008


